Personificated treatment of patients with the ovarian cancer
DOI:
https://doi.org/10.11603/2414-4533.2017.2.7951Keywords:
ovarian cancer, treatment, chemotherapy, resistance to platinum, disregulatory pathology.Abstract
The aim of the work: to improve the results of direct and long-term results of the epithelial ovarian cancer treatment by increasing the sensitivity of tumors to first-line chemotherapy.
Materials and Methods. The study involved 350 patients with ovarian cancer of III-IV stage, who underwent optimal, suboptimal or nonoptimal cytoreductive surgery. All the women were divided into two groups: group I (control group) – patients with ovarian cancer (n=50) received standard adjuvant first-line chemotherapy with platinum; group II – 300 patients who, on the basis of identified criteria sensitivity of ovarian cancer to chemotherapy by platinum drugs were divided into 3 subgroups depending on the expected impact of platinum: subgroup 1 (n=77) – patients with predictable platinum refractority, for whom treatment was started with second-line chemotherapy; subgroup 2 (n=98) – patients with predictable resistance to platinum, for whom together with the standard adjuvant first-line chemotherapy by platinum drugs we used the correction of sanogenetic disorders and disregulatory pathology; subgroup 3 (n=125) – patients with prognosed sensitivity to platinum drugs, who underwent treatment with platinum according to the standards.
Results and Discussion. Comparative analysis of data for achievement the objective effect of stabilization and control of the disease showed that, in contrast to the first group, all patients of group II managed to achieve acceptable clinical results. Overall survival in the subgroup 2 of the group II increased to 33.1±1.4 months, and in the subgroup 3 – up to 36.8±1.9 months. This corresponds ranges 5.0–71.1 months and 3.0–73.3 months, respectively.
References
Axel, M. A., Barinov, V. V., & Bokina, L. I. (2009). Lektsii po oncoginecologii [Lectures on oncogynecology]. M. : MEDpressinform, 425 p. [in Russian].
Bohman, Ya. V. (2007). Lektsii po oncoginecologii [Lectures on oncogynecology]. Moscow : MIA,. 304 p. [in Russian].
Vazhenin, A. V., Zharov, A. V., & Shimotkina, I. G. (2010). Aktualnye voprosy klinicheskoi onkoginecologii [Actual questions of clinical oncogynecology]. M. : STROM, 128 p. [in Russian].
Dubinina, V. G., Rybin, A. I., Lukyanchuk, O. V., & Kuznetsova, O. V. (2013). Analis mutaciy geniv BRCA-1 ta BRCA-2 u platynorefrakternyh pacientok z rakom yaichnikov [Analysis of mutation of BRCA-1 and BRCA-2 genes in platinum-refractory patients with ovarian cancer]. News of Naval Medicine, 1, 46–52 [in Russian].
Dubinina, V. G., Rybin, A. I., Kuznetsova, O. V., & Morozyuk, O. N. (2015). Aktivnost belka p53 u bolnyh z rakom yaichnikov v zavisimosti ot chuvstvitelnosti k preparatam platiny. [Activity of p53 protein in patients with ovarian cancer, depending on sensitivity to platinum preparations]. Klinicheskaya onkologiya – Clinical oncology, 4, 1–4 [in Russian].
Kozachenko, V. P. (Ed.) (2005). Klinicheskaya onkoginekologia [Clinical oncogynecology]. Moskov: Medicine, 376 [in Russian].
Philip, J. Dysay, & William, T. Krisman. (2011). Klinicheskaya onkoginekologia: v 3 tomah [Clinical oncogynecology: in 3 volumes]. Moscow: Practical medicine, 988 p. [in Russian].
Kolesnyk, O. O. (Ed.) Aut. : Fedorenko, Z. P., Mikhailovich, Yu. Y. & L. O. Gulak (2016). Rak v Ukraine, 2014-2015. Zahvoryuvanist, smertnist, pokaznyki diyalnosti onkologichnoi sluzhby. [Cancer in Ukraine, 2014-2015. Morbidity, mortality, the indeces of oncological service activity]. Kyiv: 17, 144 [in Ukrainian].
Svintsitsky, V. S. (2015). Seroznyi rak yaichnikov: testirovanie mutacyi genov BRCA1 and BRCA2 v Ukraini [Serous ovarian cancer: testing of mutations in the BRCA1 and BRCA2 genes in Ukraine]. Eurasian oncology journal (attachment): pp. 79–82 [in Russian].
Urmancheeva, A. F., Tyulyandina, S. A., & Moiseenko, V. M. (2008). Prakticheskaya onkoginekologia; izbrannye lekcii [Practical oncogynecology: selected lectures]. St.-Petersburg: "TOMM",. 400 p. [in Russian].
Chu, E. & De, V. T. (Ed.) (2008). Vita (translated from English) Himioterapia zlokachestvennyh opuholei [Chemotherapy of malignant neoplasms]. M. : Practice, 447 [in Russian].
Ambudakar, S. V. Dey, S., & Hrycyna, C. A. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (39), 361–398.
Chu, G. (2004). Cellular responses to cisplatin. J. Biol. Chem. (2269), 787–790.
Rybin, A. I. (2016). Personalized managing of the patients with serous ovarian cancer. ESGO Prevention in gynecological malignancies, September, 08-10, p. 35. Antalya, Turkey.
Shulman, L. P., & Dungan, J. S. (2010). Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res., 56, 69–85.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
